India, Oct. 9 -- Retension Pharmaceuticals, Inc. (RTSN), a clinical-stage biopharmaceutical company developing treatments for cardiovascular diseases, announced the pricing of its upsized initial public offering of 3.75 million shares at $12.00 per share. Retension Pharmaceuticals is developing RTN-001, a cardiovascular-targeted, next-generation PDE5 inhibitor designed to enhance nitric oxide signalling in central arteries associated with hypertension.
The gross proceeds to Retension from the offering are expected to be $45.0 million, and the offering is expected to close on or about October 13, 2026. Retension intends to use the net proceeds from the offering to complete the Phase 2b clinical trial of RTN-001 in uncontrolled hypertension ...